Dallas, TXNCT05028829Now EnrollingIRB Ready

Liver Fibrosis Clinical Trial in Dallas, TX

Access cutting-edge liver fibrosis treatment through this phase 2 clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.

Sponsored by Raymond Chung

Quick Self-Assessment

See if you qualify for this Dallas location

Preparing your pre-screening questions…

Expert Care in Dallas

Access liver fibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related liver fibrosis treatment provided free

Apply for This Dallas Location

Check if you qualify for this liver fibrosis clinical trial in Dallas, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Dallas

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Dallas site if eligible
  4. 4Begin participation

About This Liver Fibrosis Study in Dallas

Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.

Sponsor: Raymond Chung

Who Can Participate

Inclusion Criteria

Willing and able to provide informed consent
Male or female age \> 18 years at time of consent
Clinically or histologically diagnosed advanced liver fibrosis or cirrhosis, as defined by one or more of the following:
Liver biopsy demonstrating advanced fibrosis or cirrhosis (METAVIR 3-4)
Fibroscan or MR elastography consistent with advanced fibrosis or cirrhosis
Imaging showing cirrhotic-appearing liver with signs of portal hypertension
Advanced fibrosis or cirrhosis documented clinically by a treating physician
High-risk for HCC at screening according to the FIB-4 index
PLSec score ≥ 3 measured in screening blood samples from the FIB-4-high individuals.
Liver imaging within 6 months of Day 1 is required in cirrhotic subjects only, to exclude HCC
Female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
Willing and able to undergo protocol blood sampling
Subject must be able to comply with dosing instructions for study drug administration and able to complete study schedule of assessments

Exclusion Criteria

Diagnosis of any of the following forms of chronic liver disease:
alpha-1-antitrypsin (A1AT) deficiency, Wilson disease, hemochromatosis, iron overload, prior known or suspected drug-induced liver injury (DILI)
Patients with PBC, PSC, AIH, or stable hemochromatosis may be included if their liver disease etiology overlaps with that of steatotic liver disease (SLD)
Current or prior history of any of the following: \- Clinically significant illness or any other major medical disorder that in the opinion of the investigator, may interfere with subject treatment, assessment or compliance with the protocol
Known positivity for HIV infection
Active, untreated HCV infection \- Patients with prior history of HCV who achieved sustained virologic response (SVR) \>12 from Day 1 may be included in the study
Uncontrolled chronic HBV \- Patients with well controlled disease with \>12 months of stable medication use (or no medication use, in those persons for whom anti-HBV therapy is not indicated)
Clinical hepatic decompensation, defined as Child's Pugh class \>B7 or C cirrhosis \- Patients with Child's Pugh score of 7, class B, may be included in the study
History of biliary diversion
Solid organ transplant
Malignancy within the 5 years prior to screening, with the exception of specific cancers that have been cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible
Pregnant or Nursing Females (a negative serum pregnancy test is required at screening for WOCBP)
Life threatening SAE during the screening period
Subjects having the following laboratory parameters at screening
ALT \> 10 x ULN
AST \> 10 x ULN
Hemoglobin \< 8.5 g/dl
Serum creatinine \> 2.0 mg/dL
CK \> 3x ULN
Females who may wish to become pregnant and/or plan to undergo egg harvesting during the study and up to 30 days of the last dose of study drug
WOCBP must abstain from breastfeeding and be willing to use effective birth control during through the week 4 post treatment follow-up visit
Clinically relevant alcohol or drug abuse within 12 months of screening
Use of any prohibited concomitant medications as described in Section 9.1.1
Use of a statin medication within 90 days of Day 1 visit \- Subjects who are on a current statin at time of consent must be willing to undergo a 90-day washout period prior to randomization
Known hypersensitivity to atorvastatin
Current or planned participation in an investigational new drug (IND) trial from 30-days prior to randomization through the week 4 post treatment follow-up visit

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dallas?

Yes, this clinical trial (NCT05028829) has an active research site in Dallas, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Liver Fibrosis Treatment Options in Dallas, TX

If you're searching for liver fibrosis treatment options in Dallas, TX, this clinical trial (NCT05028829) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dallas research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced liver fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all liver fibrosis clinical trials near you to find additional studies recruiting in your area.

More Liver Disease Trials in Dallas, TX

See all liver disease clinical trials recruiting in Dallas — not just this study.

Browse Liver Disease Trials in Dallas →

Browse More Trials by Condition

Liver Disease TrialsFibromyalgia TrialsAll Conditions →

Ready to Join in Dallas?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Dallas, TX